<DOC>
	<DOCNO>NCT00130702</DOCNO>
	<brief_summary>The purpose study determine effective , extent , Iressa treatment acute myelogenous leukemia .</brief_summary>
	<brief_title>Study Iressa Patients With Relapsed Refractory Acute Myelogenous Leukemia</brief_title>
	<detailed_description>Patients receive Iressa daily either disease progression intolerable toxicity develop . On Day 1 treatment , physical exam bloodwork perform . Once weekly first 8 week , physical exam complete blood count differential perform . For first year , physical exam , bloodwork perform monthly . Bone marrow biopsy perform first month therapy every 3 month first year . After first year physical exam , bloodwork perform every 3 month bone marrow biopsy every 6 month .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Gefitinib</mesh_term>
	<criteria>Patients must pathologically document acute myelogenous leukemia either candidate myelosuppressive chemotherapy due age comorbid disease ; relapse acute myelogenous leukemia refractory standard therapy likely require cytoreductive therapy within 30 day . ECOG performance status 0 , 1 2 Age &gt; 18 year Adequate kidney hepatic function Greater 4 week chemotherapy , radiotherapy , immunotherapy , systemic steroid therapy exception hydroxyurea . Greater 2 month follow bone marrow peripheral blood stem cell transplantation donor lymphocyte infusion . Uncontrolled active infection Urgent need cytoreductive chemotherapy , surgery , radiotherapy Current chemotherapy chemotherapy within last 4 week . Pregnancy nurse mother Infection HIV</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>AML</keyword>
	<keyword>acute myelogenous leukemia</keyword>
	<keyword>gefitinib</keyword>
	<keyword>Iressa</keyword>
</DOC>